We anticipate sharing interim data from the KEAPSAKE trial in the second half of 2021. We currently have no plans to further develop telaglenastat in RCC. According to third-party market research, U.S. incidence of NSCLC is 192,208. In January 2021, we reported the topline results of the CANTATA trial. The primary study endpoint is PFS by blinded independent review. CB-280 is a potent and selective oral inhibitor of arginase. Arginine is an amino acid that is fundamental to the function of cytotoxic T-cells. There are a variety of available drug therapies marketed for cancer. In this event, the application must be resubmitted with the additional information. The FDA may not grant approval on a timely basis, or at all. We may never achieve or maintain profitability. &# We have never generated any revenue from product sales and may never be profitable. All of our other programs are in research and preclinical development. Some countries require approval of the sale price of a drug before it can be marketed. Insurance coverage is increasingly expensive. To the extent this in-license is terminated, our business may be harmed. Further, third parties may be dissuaded from collaborating with us. We do not currently have any registered trademarks in the United States. Physicians, on the other hand, may prescribe products for off-label uses. Our stock price has fluctuated in the past and is likely to be volatile in the future. We do not have any control over these analysts.
